- Home
- PEBK vs ELDN Comparison
PEBK vs ELDN Comparison
Compare PEBK & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEBK
- ELDN
- Stock Information
- Founded
- PEBK 1912
- ELDN 2004
- Country
- PEBK United States
- ELDN United States
- Employees
- PEBK N/A
- ELDN N/A
- Industry
- PEBK Major Banks
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- PEBK Finance
- ELDN Health Care
- Exchange
- PEBK Nasdaq
- ELDN Nasdaq
- Market Cap
- PEBK 162.7M
- ELDN 164.1M
- IPO Year
- PEBK N/A
- ELDN N/A
- Fundamental
- Price
- PEBK $30.51
- ELDN $3.98
- Analyst Decision
- PEBK
- ELDN Strong Buy
- Analyst Count
- PEBK 0
- ELDN 2
- Target Price
- PEBK N/A
- ELDN $12.50
- AVG Volume (30 Days)
- PEBK 5.7K
- ELDN 1.5M
- Earning Date
- PEBK 10-20-2025
- ELDN 11-12-2025
- Dividend Yield
- PEBK 3.15%
- ELDN N/A
- EPS Growth
- PEBK 3.81
- ELDN N/A
- EPS
- PEBK 3.06
- ELDN 0.21
- Revenue
- PEBK $85,500,000.00
- ELDN N/A
- Revenue This Year
- PEBK N/A
- ELDN N/A
- Revenue Next Year
- PEBK N/A
- ELDN N/A
- P/E Ratio
- PEBK $10.10
- ELDN $18.77
- Revenue Growth
- PEBK 6.88
- ELDN N/A
- 52 Week Low
- PEBK $23.74
- ELDN $2.32
- 52 Week High
- PEBK $33.90
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- PEBK 49.06
- ELDN 76.48
- Support Level
- PEBK $29.16
- ELDN $3.18
- Resistance Level
- PEBK $31.95
- ELDN $3.76
- Average True Range (ATR)
- PEBK 0.70
- ELDN 0.31
- MACD
- PEBK 0.13
- ELDN 0.10
- Stochastic Oscillator
- PEBK 55.13
- ELDN 100.00
About PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.